Numbers

Figures converted from CAD at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

The Numbers

NexgenRx is a $21M USD Canadian micro-cap that runs claims adjudication software for third-party insurers and self-insured employer benefit plans. FY2025 revenue of $12.8M grew 8.8% and, crucially, dropped $3.3M of free cash flow into the till — a jump that followed a multi-year margin reset and finally lifts the five-year story back above water. The single number most likely to rerate this stock is operating margin: it oscillates between 12% highs (FY2020, FY2025) and 0–2% lows (FY2022, FY2023, FY2024), so whether the FY2025 print is signal or noise determines everything. The 20-year P/S history sits at 4.4x, the current 1.7x; today's multiple reflects a market that has seen this company flatter-to-flat before and is not yet paying for durable operating leverage.

Snapshot

At $0.28, NXG.V trades about 10% above the 12-month Fair Value estimate of $0.25 — mild over-valuation against the quantitative model, not dramatic. Scale remains tiny: a $22M USD market cap versus Canadian group-insurance peers in the tens of billions.

Quality scorecard

The 59/100 composite is middle-of-pack — not broken, not excellent. The blemish is Predictability of 1 (out of 5): earnings have whipsawed between profit and loss for two decades, and the model has almost no confidence in forward EPS. Altman Z, Piotroski F, and Beneish M are not computed for this micro-cap (too few comparable data points), so we are left reading the component ranks directly.

Revenue and earnings power — 20-year view

Revenue compounds — 14.3% over 10 years, 10.2% over 5 years — but the line never goes vertical. What moves the stock is the operating-income line, which has flipped sign eight times in twenty years. FY2025 is the first print that clears 12% operating margin in four years; whether that holds is the entire question.

Quarterly pulse (last 16Q)

Quarterly operating income is the story — every one of the last four quarters was positive, the first such streak in the dataset, and operating margins have averaged 13.7% across FY2025. That is the number an investor is either paying for or discounting.

Cash generation

Free cash flow has consistently exceeded net income since FY2020 — the trailing five-year FCF/NI conversion ratio is ~1.7x ($6.8M of cumulative FCF on $4.0M of cumulative net income). Depreciation and amortisation of intangible platform assets (~$0.9–1.0M/yr) are the bridge: the income statement absorbs non-cash charges while cash keeps flowing. FY2025's $3.3M FCF is a step-change up.

Capital allocation

Since FY2022 the playbook has been clear: dividend the cash out, keep debt near zero, let stock-based comp wither to nothing. No buybacks, no M&A, no new equity issuance after FY2018. Dividends totalling $0.93M on FY2025 FCF of $3.3M means payout is ~28% — leaving real reinvestment optionality that management has not yet deployed.

Balance sheet health

NexgenRx carries zero long-term debt, $3.4M in cash (16% of market cap), and equity of $5.5M. The 2018–2019 spike in leverage (debt-to-equity ~2x) funded an acquisition of intangible assets; since FY2020 the company has deleveraged to roughly zero. Historical losses still show: retained earnings are negative $1.8M despite profitability — but down from negative $16M ten years ago, which is the real accomplishment.

Valuation — 20-year self-history

The most appropriate multiple here is P/S, because operating earnings are too erratic to stabilise P/E. Today's 1.7x P/S is below the 20-year mean (~4.4x — inflated by the 2006–2010 pre-scale era) but above the five-year mean of 1.6x. EV/EBITDA at 8.1x is meaningfully below the 10-year positive-EBITDA average of 13.3x — consistent with a market assigning little credit for margin durability. When the business loses money, the multiple goes meaningless; when it makes money, the multiple compresses toward commodity levels.

Peer comparison

NXG.V is 1,500x smaller than the smallest peer on this table. The strategic pick for a peer set is the big Canadian insurers (Sun Life, Manulife, Great-West, iA) plus TELUS Health — the incumbents whose captive TPA arms compete directly with NexgenRx's independent offering. On growth, NXG is in line (8.8% vs 10–15% peers). On margin, NexgenRx's 7.2% net margin is below every peer except TELUS; for a software/services business that 80%+ gross margin would ordinarily translate into 15–25% net margin, the gap to the insurers is conspicuous and tells you operating costs still eat most of the gross profit.

Fair value and scenarios

Base case $0.25 is the quantitative Fair Value — implies a modest 10% drawdown from today. Bear $0.16 pulls the stock back to the FY2023 low multiple of 1.1x P/S on FY2025 revenue, which is what happens if margins re-soften. Bull $0.39 rewards a stabilised 12% operating margin with a 2.5x P/S, the FY2021 high. Each scenario turns on the same margin question, not on revenue.

What the numbers say

Confirm: Revenue compounds double-digit, gross margin is software-like at 80%+, the balance sheet carries no debt, and FY2025 was a genuine breakout in cash flow and operating leverage.

Contradict: The "only independent TPA" narrative would imply a durable moat and premium multiple; the market pays 1.7x sales — a commodity services multiple — because margins have reverted three times in five years.

Watch next quarter/year: 1Q26 operating margin. If it clears 10%, the FY2025 pattern is structural; under 5%, the thesis is noise. Secondary tell: whether a richer $3.4M cash balance funds an acquisition, buyback, or special dividend — capital-deployment discipline is the one thing a micro-cap can control.